179 related articles for article (PubMed ID: 22203591)
1. Comparative pharmacodynamics and antimutant potentials of doripenem and imipenem with ciprofloxacin-resistant Pseudomonas aeruginosa in an in vitro model.
Firsov AA; Gilbert D; Greer K; Portnoy YA; Zinner SH
Antimicrob Agents Chemother; 2012 Mar; 56(3):1223-8. PubMed ID: 22203591
[TBL] [Abstract][Full Text] [Related]
2. Concentration-resistance relationships with Pseudomonas aeruginosa exposed to doripenem and ciprofloxacin in an in vitro model.
Zinner SH; Gilbert D; Greer K; Portnoy YA; Firsov AA
J Antimicrob Chemother; 2013 Apr; 68(4):881-7. PubMed ID: 23175594
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents.
Fujimura T; Anan N; Sugimori G; Watanabe T; Jinushi Y; Yoshida I; Yamano Y
Int J Antimicrob Agents; 2009 Dec; 34(6):523-8. PubMed ID: 19748767
[TBL] [Abstract][Full Text] [Related]
4. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
Hu YF; Liu CP; Wang NY; Shih SC
BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962
[TBL] [Abstract][Full Text] [Related]
5. Activity of doripenem against extended-spectrum beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa isolates.
Betriu C; Gómez M; López-Fabal F; Culebras E; Rodríguez-Avial I; Picazo JJ
Eur J Clin Microbiol Infect Dis; 2010 Sep; 29(9):1179-81. PubMed ID: 20521156
[TBL] [Abstract][Full Text] [Related]
6. Comparative In Vitro Efficacy of Doripenem and Imipenem Against Multi-Drug Resistant Pseudomonas aeruginosa.
Wali N; Mirza IA
J Coll Physicians Surg Pak; 2016 Apr; 26(4):297-301. PubMed ID: 27097701
[TBL] [Abstract][Full Text] [Related]
7. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem.
Riera E; Cabot G; Mulet X; García-Castillo M; del Campo R; Juan C; Cantón R; Oliver A
J Antimicrob Chemother; 2011 Sep; 66(9):2022-7. PubMed ID: 21653605
[TBL] [Abstract][Full Text] [Related]
8. Predictors of bacterial resistance using in vitro dynamic models: area under the concentration-time curve related to either the minimum inhibitory or mutant prevention antibiotic concentration.
Strukova EN; Portnoy YA; Zinner SH; Firsov AA
J Antimicrob Chemother; 2016 Mar; 71(3):678-84. PubMed ID: 26626718
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics of the antibacterial effect of and emergence of resistance to doripenem in Pseudomonas aeruginosa and Acinetobacter baumannii in an in vitro pharmacokinetic model.
Bowker KE; Noel AR; Tomaselli SG; Elliott H; Macgowan AP
Antimicrob Agents Chemother; 2012 Oct; 56(10):5009-15. PubMed ID: 22713338
[TBL] [Abstract][Full Text] [Related]
10. Interpreting carbapenem susceptibility testing results for Pseudomonas aeruginosa.
Micaëlo M; Brossier F; Bréchot N; Luyt CE; Lu Q; Monsel A; Jarlier V; Aubry A
Med Mal Infect; 2018 Aug; 48(5):365-371. PubMed ID: 29628176
[TBL] [Abstract][Full Text] [Related]
11. [Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study].
Korten V; Söyletir G; Yalçın AN; Oğünç D; Dokuzoğuz B; Esener H; Ulusoy S; Tünger A; Aygen B; Sümerkan B; Arman D; Dizbay M; Akova M; Hasçelik G; Eraksoy H; Başaran S; Köksal I; Bayramoğlu G; Akalın H; Sınırtaş M
Mikrobiyol Bul; 2011 Apr; 45(2):197-209. PubMed ID: 21644063
[TBL] [Abstract][Full Text] [Related]
12. Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance.
Louie A; Bied A; Fregeau C; Van Scoy B; Brown D; Liu W; Bush K; Queenan AM; Morrow B; Khashab M; Kahn JB; Nicholson S; Kulawy R; Drusano GL
Antimicrob Agents Chemother; 2010 Jun; 54(6):2638-45. PubMed ID: 20308371
[TBL] [Abstract][Full Text] [Related]
13. In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures.
Kim A; Banevicius MA; Nicolau DP
Antimicrob Agents Chemother; 2008 Jul; 52(7):2497-502. PubMed ID: 18458125
[TBL] [Abstract][Full Text] [Related]
14. Comparative Activity of Carbapenem Testing (COMPACT) study in Germany.
Valenza G; Seifert H; Decker-Burgard S; Laeuffer J; Morrissey I; Mutters R;
Int J Antimicrob Agents; 2012 Mar; 39(3):255-8. PubMed ID: 22230334
[TBL] [Abstract][Full Text] [Related]
15. [Comparative activity of doripenem, meropenem, and imipenem in recent clinical isolates obtained during the COMPACT-Spain epidemiological surveillance study].
Gimeno C; Cantón R; García A; Gobernado M;
Rev Esp Quimioter; 2010 Sep; 23(3):144-52. PubMed ID: 20844845
[TBL] [Abstract][Full Text] [Related]
16. Predicting doripenem susceptibility based on meropenem and imipenem interpretation for Pseudomonas aeruginosa.
Hagihara M; Kuti JL; Nicolau DP
Diagn Microbiol Infect Dis; 2012 Mar; 72(3):258-62. PubMed ID: 22209563
[TBL] [Abstract][Full Text] [Related]
17. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
Zinner SH; Vostrov SN; Alferova IV; Lubenko IY; Portnoy YA; Firsov AA
Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
[TBL] [Abstract][Full Text] [Related]
18. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
Goff DA; Nicolau DP
Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574
[TBL] [Abstract][Full Text] [Related]
19. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential.
Mushtaq S; Ge Y; Livermore DM
Antimicrob Agents Chemother; 2004 Aug; 48(8):3086-92. PubMed ID: 15273124
[TBL] [Abstract][Full Text] [Related]
20. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
Sumitani Y; Kobayashi Y
Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]